Тромботические события при редких формах генетических тромбофилий
УДК 616.15-008.1
Аннотация
Резюме. Цель исследования: изучить лабораторный фенотип редких мутаций Лейдена [FVL А(1961)A] и гена протромбина [FII А(20210)A] при их клинической реализации в виде тромбозов. Материалы и методы. Проведено многоцентровое проспективное наблюдательное исследование, включающее 80 носителей редких генетических форм тромбофилий: FVL А(1961)A (n=31), FII А(20210)A (n=10) и компаунд FII G(20210)A+FVL G(1691)A (n=39). У всех пациентов исследована резистентность фактора Va к активированному протеину С (APC-R) по нормализованному отношению (НО) и уровень активности протромбина в плазме крови в состоянии физического здоровья и в случае эпизода тромботического события. Результаты. Определена ассоциативная связь развития тромботических событий со снижением НО при оценке APC-R как у гомозиготных носителей мутации Лейден (Ме = 0,35; 95% ДИ = 0,31–0,37 по НО), так и гетерозиготных компаундов (Ме=0,43; 95% ДИ=0,42–0,45 по НО). Заключение. Лабораторный мониторинг пациентов с редкими формами генетических тромбофилий позволяет выделить группу высокого тромбогенного риска, нуждающуюся в пролонгированной тромбопрофилактике.Литература
- Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516–30.
- Bates S.M., Greer I.A., Pabinger I. et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):844S-6S. DOI: 10.1378/chest.08–0761.
- Thrombophilia. Prevention and treatment of venous thromboembolism. International Consensus Statement (Guidelines according to scientific evidence). Int Angiol. 2005;24(1):1–26.
- Nicolaides A.N., Fareed J., Kakkar A.K. et al. Prevention and treatment of venous thromboembolism — International Consensus Statement. Int Angiol. 2013;32(2):111–260.
- American College of Obstetricians and Gynecologists Women’s Health Care Physicians. ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2013;122(3):706–17. DOI: 10.1097/01.AOG.0000433981.36184.4e.
- Dilley A., Austin H., Hooper W.C. et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med. 1998;132(6):452–5. DOI: 10.1016/s0022– 2143(98)90121–4.
- Rosendaal F.R., Doggen C.J., Zivelin A. et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79(4):706–8.
- Капустин С.И., Блинов М.Н., Папаян Л.П., Селиванов Е.А. Наследственная тромбофилия — актуальная проблема современной медицины. Медицинский академический журнал. 2006;6(1):183–92.
- Ridker P.M., Miletich J.P., Hennekens C.H., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277(16):1305–7.
- Bosler D, Mattson J, Crisan D. Phenotypic heterogeneity in patients with homozygous prothrombin 20210AA genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006;8(4):420–5. DOI: 10.2353/ jmoldx.2006.060014.
- Kosch A., Junker R., Wermes C., Nowak-Göttl U. Recurrent pulmonary embolism in a 13-year-old male homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased lipoprotein (a). Thromb Res. 2002;105(1):49–53. DOI: 10.1016/s0049–3848(01)00406–6.
- Klein L., Bhardwaj V., Gebara B. Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype. J Perinatol. 2004;24(12):797–9. DOI: 10.1038/sj.jp.7211187.
- Cooper D.N., Krawezak M. Venous thrombosis: from genes to clinical medicine. BIOS Scientific Publishers Ltd, 1997. 368 p.
- Dizon-Townson D.S., Meline L., Nelson L.M. et al. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol. 1997;177(2):402–5. DOI: 10.1016/s0002–9378(97)70205
- Simone B., De Stefano V., Leoncini E. et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–47. DOI: 10.1007/ s10654–013–9825–8.
- Cohen W., Castelli C., Suchon P. et al. Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model. J Thromb Haemost. 2014;12(2):138–46. DOI: 10.1111/jth.12461.
- Chang M.H., Lindegren M.L., Butler M.A. et al. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991–1994. Am J Epidemiol. 2009;169(1):54–66. DOI: 10.1093/aje/kwn286.
- Emmerich J., Rosendaal F.R., Cattaneo M. et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism — pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86(3):809–16.
- González-Porras J.R., García-Sanz R., Alberca I. et al. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. Blood Coagul Fibrinolysis. 2006;17(1):23–8. DOI: 10.1097/01. mbc.0000201488.33143.09.
- CrolesF.N.,MulderR.,MulderA.B.etal.β-Antithrombin,subtype of antithrombin deficiency and the risk of venous thromboembolism in hereditary antithrombin deficiency: A family cohort study. Thromb Res. 2018;168:47–52. DOI: 10.1016/j.thromres.2018.06.004.
- Corral J., de la Morena-Barrio M.E., Vicente V.The genetics of antithrombin. Thromb Res. 2018;169:23–9. DOI: 10.1016/j. thromres.2018.07.008.
- Momot A.P., Semenova N.A., Belozerov D.E. et al. The Dynamics of the hemostatic parameters in physiological pregnancy and after delivery. J Hematol Blood Transfus Disord. 2016;3:005. DOI: 10.24966/HBTD-2999/100005.
- Hillarp A., Dahlbäck B., Zöller B. Activated protein C resistance: from phenotype to genotype and clinical practice. Blood Rev. 1995;9(4):201–12. DOI: 10.1016/s0268–960x(95)90011-x.
- Castaman G., Tosetto A., Simioni M. et al. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thromb Haemost. 2001;86(3):804–8.
- Tripodi A., Chantarangkul V., Mannucci P.M. Hyperprothrombinemia may result in acquired activated protein C resistance. Blood. 2000;96(9):3295–6.
- Castoldi E., Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010;8(3):445–53. DOI: 10.1111/j.1538–7836.2009.03711.x.
Ключевые слова
мутация Лейден, мутация гена протромбина, тромбозы, резистентность фактора Va к активированному протеину С, активность протромбина